Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravaginal artesunate as adjuvant treatment for HPV and cervical precancer in women living with HIV
PACTR202406532417953Phase 2Not yet recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of artesunate in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Clearance of type-specific HPV genotype(s). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
artesunate
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on PACTR202406532417953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202406532417953.